|
|
World's First Plant-made Vaccine Registered
Jan 31, 2006, 21:58, Reviewed by: Dr. Priya Saxena
|
|
"Being the first company to ever register a plant-made vaccine is another example of Dow AgroSciences' cutting edge approach to bringing highly novel and differentiated solutions to the market"
|
By RxPG News,
Dow AgroSciences LLC, a wholly owned subsidiary of The Dow Chemical Company, announced today that it has received the world's first regulatory approval for a plant-made vaccine from the United States Department of Agriculture (USDA) Center for Veterinary Biologics. This approval represents an innovative milestone for the company and the industry.
"With this achievement Dow AgroSciences is revolutionizing the field of preventative medicine with plant-cell-produced vaccines," said Butch Mercer, Dow AgroSciences' global business leader for Animal Health.
The Dow AgroSciences ConcertTM Plant-Cell-Produced System represents a new category of plant-made vaccines. This leading edge technology utilizes plant cells instead of whole plants in a secure, bio-contained environment to produce vaccines. Because of this bio-contained production system, concerns and challenges associated with making vaccines in whole plants or food crops are eliminated.
"Being the first company to ever register a plant-made vaccine is another example of Dow AgroSciences' cutting edge approach to bringing highly novel and differentiated solutions to the market," said Jerome Peribere, Dow AgroSciences' president and CEO.
The ConcertTM Plant-Cell-Produced System uses only the necessary parts of the disease causing agent to stimulate immunity in a manufacturing process that is totally free of animal components. According to John Cuffe, Dow AgroSciences' R&D leader for Animal Health, "This approval is a perfect example of how biotechnology is advancing science by creating a new category of vaccines that is both safe and effective."
By achieving this regulatory milestone, Dow AgroSciences has demonstrated that this new technology fits within the existing USDA Center for Veterinary Biologics regulatory approval process. Dow AgroSciences can now focus its efforts on developing new, innovative vaccines with an emphasis on animal health. Possible target animals include: horses, companion animals (such as dogs and cats), poultry, swine, and cattle. Furthermore, utilizing this revolutionary technology for human diseases is a real possibility.
This milestone achievement by Dow AgroSciences was the result of effective collaborations with prominent organizations and institutions including Washington University, Boyce Thompson Institute for Plant Research, Benchmark Biolabs, Inc., and The Biodesign Institute at Arizona State University. In less than five years Dow AgroSciences moved the science forward, established a production facility, and received this regulatory approval. 
- Dow AgroSciences
www.dowagro.com
Dow AgroSciences is growing through an ambitious program of scientific discovery that creates new, revolutionary solutions. The ConcertTM Plant-Cell-Produced System demonstrates how Dow AgroSciences is applying innovation to safely put the power of prevention to work.
Dow AgroSciences LLC, based in Indianapolis, Indiana, USA, is a global leader in providing pest management, agricultural seed and biotechnology products that improve the quality and quantity of the earth's food supply and contribute to the health and quality of life of the world's growing population. Dow AgroSciences has approximately 5,500 people in more than 50 countries dedicated to its business, and has worldwide sales of US $3.4 billion. Dow AgroSciences is a wholly owned subsidiary of The Dow Chemical Company.
|
For any corrections of factual information, to contact the editors or to send
any medical news or health news press releases, use
feedback form
Top of Page
|
|
|
|
